Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou 310007, China.
J Tradit Chin Med. 2019 Aug;39(4):535-541.
To investigate the effects of the Traditional Chinese Medicine Qishan granules (TCM Qishan) on glucose and lipid metabolism, plasma adiponectin, and insulin resistance (IR) in a rat model of prediabetes.
A prediabetic rat model was established by high-fat diet-feeding. Sugar-free Qishan granules, rosiglitazone, or no treatment were then administered for 10 weeks, after which body mass, fasting blood glucose (FBG), 2-h postprandial blood glucose (2hPG), hemoglobin A1c (HbA1c), fasting insulin (FINS), 2-h postprandial insulin (2hINS), plasma adiponectin (APN), plasma lipids, and free fatty acids (FFA), and liver pathology, were assessed.
The mean mass of the rats treated with various doses of TCM Qishan was significantly lower (P < 0.01) than that of the prediabetic control rats, and that of the rats treated with a high dose of TCM Qishan was significantly lower (P < 0.01) than that of those treated with rosiglitazone. Metabolic indexes and IR were similarly improved by TCM Qishan and rosiglitazone treatment, with FBG, 2hPG, HbA1c, FINS, 2hINS, plasma triglyceride (TG), and FFA levels being significantly lower (P < 0.01), and APN concentration being significantly higher, in both of these treatment groups, than those of the prediabetic control group. The plasma total cholesterol and low-density lipoprotein-cholesterol concentrations of the treatment groups were also significantly lower (P < 0.05 and P < 0.01, respectively) than those of the prediabetic control group, but there were no significant differences in high-density lipoprotein-cholesterol concentrations. A high dose of TCM Qishan was slightly more effective than rosiglitazone at reducing TG concentration. The prediabetic control rats demonstrated severe hepatic steatosis, and the high dose of TCM Qishan significantly ameliorated this.
TCM Qishan significantly reduces weight gain, ameliorates defects in glucose and lipid metabolism, and increases insulin sensitivity and plasma APN concentration in prediabetic rats. The effect of TCM Qishan on body mass was superior to that of rosiglitazone, and its other effects were of similar magnitude.
观察芪山颗粒对糖尿病前期大鼠血糖、血脂代谢及血浆脂联素、胰岛素抵抗的影响。
采用高脂饲料喂养建立糖尿病前期大鼠模型，给予无糖芪山颗粒、罗格列酮或空白对照治疗 10 周，观察大鼠体重、空腹血糖（FBG）、餐后 2 小时血糖（2hPG）、糖化血红蛋白（HbA1c）、空腹胰岛素（FINS）、餐后 2 小时胰岛素（2hINS）、血浆脂联素（APN）、血脂、游离脂肪酸（FFA）及肝组织病理学变化。
芪山颗粒各剂量组大鼠体重较糖尿病前期模型组明显降低（P＜0.01），高剂量组大鼠体重较罗格列酮组明显降低（P＜0.01）；芪山颗粒和罗格列酮均可改善大鼠代谢指标和胰岛素抵抗，表现为 FBG、2hPG、HbA1c、FINS、2hINS、血浆三酰甘油（TG）、FFA 水平明显降低（P＜0.01），APN 浓度明显升高，与糖尿病前期模型组比较差异均有统计学意义；两组大鼠血浆总胆固醇、低密度脂蛋白胆固醇水平较糖尿病前期模型组明显降低（P＜0.05 和 P＜0.01），高密度脂蛋白胆固醇水平差异无统计学意义；芪山颗粒高剂量组降低 TG 作用优于罗格列酮组。糖尿病前期模型组大鼠肝脏出现严重的脂肪变性，芪山颗粒高剂量组可明显改善这一情况。
芪山颗粒可显著减轻糖尿病前期大鼠体重增长，改善糖、脂代谢紊乱，提高胰岛素敏感性，增加血浆 APN 浓度，其作用优于罗格列酮，在改善体重和其他方面与罗格列酮相当。
